- JP-listed companies
- ReproCELL Incorporated
- Income statement
ReproCELL Incorporated【JP:4978】Income statement
Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Revenue | 317 | 420 | 461 | 567 | 1,066 | 1,258 | 926 | 1,089 | 1,200 | 1,286 | 2,235 | 2,953 | 2,427 | 2,979 |
| Revenue growth (%) | - | |||||||||||||
| Cost of revenue | - | - | - | 291 | 533 | 682 | 545 | 592 | 725 | 804 | 1,431 | 1,812 | 1,306 | 1,330 |
| Gross profit | - | - | - | 276 | 533 | 576 | 381 | 496 | 475 | 483 | 803 | 1,141 | 1,121 | 1,649 |
| Gross margin (%) | - | - | - | |||||||||||
| Operating margin (%) | - | - | - | |||||||||||
| Operating expenses | - | - | - | 1,017 | 1,557 | 1,520 | 1,407 | 1,278 | 1,384 | 1,531 | 1,451 | 1,497 | 1,530 | 1,779 |
| Operating income | - | - | - | -741 | -1,024 | -944 | -1,026 | -781 | -909 | -1,048 | -647 | -356 | -409 | -130 |
| Income before tax | -21 | 7 | -133 | -457 | -1,170 | -937 | -935 | -627 | -892 | -789 | -507 | -120 | 40 | 45 |
| Pretax margin (%) | -6.6 | 1.7 | -28.8 | -80.6 | -109.7 | -74.5 | -100.9 | -57.6 | -74.3 | -61.3 | -22.7 | -4.1 | 1.7 | 1.5 |
| Provision for income taxes | - | - | - | -5 | -18 | -22 | -110 | 1 | 2 | 2 | 1 | 2 | 3 | -57 |
| Effective tax rate (%) | - | - | - | |||||||||||
| Net income | -22 | 6 | -119 | -452 | -1,961 | -912 | -2,172 | -601 | -1,017 | -813 | -575 | -305 | -31 | 103 |
| Net income margin (%) | ||||||||||||||
| Earnings per share | -2.9 | 0.15 | -3.08 | -9.01 | -36.16 | -15.68 | -34.28 | -8.79 | -14.27 | -11.38 | -7.57 | -3.62 | -0.37 | 1.11 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | |||||||||||
| EBITDA margin (%) | - | - | - |